Dirk Trommeshauser

864 total citations
21 papers, 713 citations indexed

About

Dirk Trommeshauser is a scholar working on Oncology, Cell Biology and Cancer Research. According to data from OpenAlex, Dirk Trommeshauser has authored 21 papers receiving a total of 713 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Cell Biology and 5 papers in Cancer Research. Recurrent topics in Dirk Trommeshauser's work include Microtubule and mitosis dynamics (9 papers), Cancer Treatment and Pharmacology (4 papers) and Cancer-related Molecular Pathways (4 papers). Dirk Trommeshauser is often cited by papers focused on Microtubule and mitosis dynamics (9 papers), Cancer Treatment and Pharmacology (4 papers) and Cancer-related Molecular Pathways (4 papers). Dirk Trommeshauser collaborates with scholars based in Germany, Spain and Australia. Dirk Trommeshauser's co-authors include Gerd Munzert, Arne Ring, R. Kaiser, Klaus A. Dugi, Tim Heise, Eva U. Graefe-Mody, Annette Frost, Simone Steinbild, K. Mross and Susanne Hedbom and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Dirk Trommeshauser

21 papers receiving 699 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dirk Trommeshauser Germany 14 284 254 215 156 79 21 713
Zhousheng Xiao China 11 265 0.9× 435 1.7× 69 0.3× 61 0.4× 82 1.0× 12 986
Yoshiki Amuro Japan 17 222 0.8× 341 1.3× 96 0.4× 57 0.4× 104 1.3× 52 735
Quang T. Luong United States 11 168 0.6× 419 1.6× 107 0.5× 79 0.5× 29 0.4× 16 754
Thomas Schlüter Germany 18 203 0.7× 298 1.2× 130 0.6× 26 0.2× 17 0.2× 28 786
Kenji Ohwaki Japan 18 112 0.4× 341 1.3× 46 0.2× 136 0.9× 56 0.7× 30 866
Zelin Sheng United States 9 212 0.7× 690 2.7× 37 0.2× 101 0.6× 28 0.4× 12 1.1k
Gérard Sanderink France 11 412 1.5× 243 1.0× 39 0.2× 28 0.2× 37 0.5× 17 866
Mary A. Root United States 17 135 0.5× 301 1.2× 106 0.5× 253 1.6× 58 0.7× 40 963
Karin Conde‐Knape United States 14 82 0.3× 240 0.9× 62 0.3× 213 1.4× 22 0.3× 27 686
Weizheng Xu United States 17 645 2.3× 555 2.2× 41 0.2× 53 0.3× 41 0.5× 23 1.1k

Countries citing papers authored by Dirk Trommeshauser

Since Specialization
Citations

This map shows the geographic impact of Dirk Trommeshauser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dirk Trommeshauser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dirk Trommeshauser more than expected).

Fields of papers citing papers by Dirk Trommeshauser

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dirk Trommeshauser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dirk Trommeshauser. The network helps show where Dirk Trommeshauser may publish in the future.

Co-authorship network of co-authors of Dirk Trommeshauser

This figure shows the co-authorship network connecting the top 25 collaborators of Dirk Trommeshauser. A scholar is included among the top collaborators of Dirk Trommeshauser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dirk Trommeshauser. Dirk Trommeshauser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dallinger, Claudia, Dirk Trommeshauser, Kristell Marzin, et al.. (2016). Pharmacokinetic Properties of Nintedanib in Healthy Volunteers and Patients With Advanced Cancer. The Journal of Clinical Pharmacology. 56(11). 1387–1394. 45 indexed citations
2.
Frost, Annette, K. Mross, Simone Steinbild, et al.. (2012). Phase I Study of the Plk1 Inhibitor BI 2536 Administered Intravenously on Three Consecutive Days in Advanced Solid Tumours. Current Oncology. 19(1). 28–35. 62 indexed citations
3.
Mendizábal, Nieves Vélez de, et al.. (2012). Joint Population Pharmacokinetic/Pharmacodynamic Model for the Heart Rate Effects at Rest and at the End of Exercise for Cilobradine. Pharmaceutical Research. 30(4). 1110–1122. 5 indexed citations
4.
5.
6.
Staab, Alexander, Christiane Tillmann, Dirk Trommeshauser, et al.. (2010). Semi-mechanistic population pharmacokinetic/pharmacodynamic model for neutropenia following therapy with the Plk-1 inhibitor BI 2536 and its application in clinical development. Cancer Chemotherapy and Pharmacology. 66(4). 785–795. 20 indexed citations
7.
Lehr, Thorsten, Alexander Staab, Dirk Trommeshauser, Hans Schaefer, & Charlotte Kloft. (2010). Quantitative Pharmacology Approach in Alzheimer’s Disease: Efficacy Modeling of Early Clinical Data to Predict Clinical Outcome of Tesofensine. The AAPS Journal. 12(2). 117–129. 10 indexed citations
8.
Hofheinz, Ralf‐Dieter, Salah‐Eddin Al‐Batran, Andreas Hochhaus, et al.. (2010). An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BI 2536, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 16(18). 4666–4674. 78 indexed citations
9.
Lehr, Thorsten, et al.. (2009). A Quantitative Enterohepatic Circulation Model. Clinical Pharmacokinetics. 48(8). 529–542. 31 indexed citations
10.
Lehr, Thorsten, Alexander Staab, Dirk Trommeshauser, Hans Schaefer, & Charlotte Kloft. (2009). Semi-Mechanistic Population Pharmacokinetic Drug-Drug Interaction Modelling of a Long Half-Life Substrate and Itraconazole. Clinical Pharmacokinetics. 49(1). 53–66. 14 indexed citations
11.
12.
Vose, Julie M., Jonathan W. Friedberg, Edmund K. Waller, et al.. (2008). Phase I Dose-Escalation Trial of BI 2536, a Polo-Like Kinase 1 Inhibitor, in Relapsed and Refractory Non-Hodgkin’s Lymphoma. Blood. 112(11). 233–233. 6 indexed citations
13.
Ellis, Peter, Quincy S. Chu, N. B. Leighl, et al.. (2008). A phase I dose escalation trial of BI 2536, a novel Plk1 inhibitor, with standard dose pemetrexed in previously treated advanced or metastatic non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 26(15_suppl). 8115–8115. 13 indexed citations
14.
Mross, K., Annette Frost, Simone Steinbild, et al.. (2008). Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 26(34). 5511–5517. 129 indexed citations
15.
Staab, Alexander, et al.. (2007). Population Pharmacokinetic Data Analysis of Cilobradine, an If Channel Blocker. Pharmaceutical Research. 25(2). 359–368. 10 indexed citations
16.
Lehr, Thorsten, Alexander Staab, Christiane Tillmann, et al.. (2007). Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease. British Journal of Clinical Pharmacology. 64(1). 36–48. 15 indexed citations
17.
Lehr, Thorsten, Alexander Staab, Christiane Tillmann, et al.. (2007). Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic‐pharmacodynamic modelling approach. British Journal of Pharmacology. 153(1). 164–174. 26 indexed citations
18.
Munzert, Gerd, Simone Steinbild, Annette Frost, et al.. (2006). A phase I study of two administration schedules of the Polo-like kinase 1 inhibitor BI 2536 in patients with advanced solid tumors. Journal of Clinical Oncology. 24(18_suppl). 3069–3069. 13 indexed citations
19.
Trommeshauser, Dirk, K. Mross, Simone Steinbild, et al.. (2006). 401 POSTER Pharmacokinetic characterization of BI 2536 - a novel Plk1 inhibitor - in advanced cancer patients. European Journal of Cancer Supplements. 4(12). 123–123. 2 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhousheng Xiao Breakdown of academic impact, for papers by Yoshiki Amuro Breakdown of academic impact, for papers by Quang T. Luong Breakdown of academic impact, for papers by Thomas Schlüter Breakdown of academic impact, for papers by Kenji Ohwaki Breakdown of academic impact, for papers by Zelin Sheng Breakdown of academic impact, for papers by Gérard Sanderink Breakdown of academic impact, for papers by Mary A. Root Breakdown of academic impact, for papers by Karin Conde‐Knape Breakdown of academic impact, for papers by Weizheng Xu
Rankless by CCL
2026